19.11.2014 • NewsCatalentADCMergers & Acquisitions (M&A)

Catalent Acquires Micron Technologies

Catalent, a leading US supplier of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Micron Technologies, a specialist in particle size engineering technologies.

With the addition of Micron's capabilities to its own suite of drug delivery and development solutions, Catalent said it can now partner with more pharmaceutical innovators at the earliest stages of the drug development process, including scale-up, clinical and commercial manufacturing of finished oral and inhaled dose forms including for highly potent compounds.

Micron Technologies currently operates two state-of-the-art facilities at Malvern, Pennsylvania in the US and Dartford UK. Together the sites employ around 100 people.

The acquisition is Catalent's second since its initial public offering in July of this year and follows the acquisition of Redwood Bioscience, with its SMARTag Antibody-Drug Conjugate (ADC) technology platform, in October 2014.

Earlier in November, the US drug delivery specialist said it had begun work on expanding its highly potent and cytotoxic clinical drug packaging capabilities at its campus in Kansas City, MO campus. The expansion will add two large packaging suites, a sampling lab, and space for various storage conditions.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.